## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.78 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (41% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($39.19)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Veracyte (NASDAQ:VCYT) Raised to Strong-Buy at Wall Street Zen**
- Source: MarketBeat | 20251227T070927 | Bullish | Relevance: 100%
- Wall Street Zen has upgraded Veracyte (NASDAQ:VCYT) to a "strong-buy" rating, with other analysts also raising price targets, contributing to a "Moderate Buy" consensus and a $45.43 target price from MarketBeat. The company recently exceeded earnings expectations, reporting an EPS of $0.51 against an anticipated $0.32, and revenue of $131.9M compared to an expected $124.6M, representing a 13.8% year-over-year increase. Despite recent insider selling, institutional investors have shown increased interest, with several hedge funds and investment firms adding to their positions in Veracyte.

**2. Veracyte, Inc. $VCYT Shares Sold by Assenagon Asset Management S.A.**
- Source: MarketBeat | 20251225T130927 | Neutral | Relevance: 100%
- Assenagon Asset Management S.A. significantly reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 96.7% in the third quarter, selling 803,061 shares. Company insiders, including Director Karin Eastham and SVP Annie McGuire, also offloaded shares totaling over $6.28 million. Despite these sales, Veracyte reported strong Q3 earnings, beating analyst estimates, and currently holds a "Moderate Buy" consensus rating with a target price of $45.43.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 25 ($5.77M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Insider selling cluster: $5.8M in recent transactions.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (1 raises, avg +20%). Insider selling cluster ($5.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 26.5 |
| Current P/E | 25.8 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -4.5% (minimal 5-day change). Below STRENGTH zone by 8.5pp (needs >4.0% for momentum thesis). AM_20 at -3.6% indicates price below own 20MA trend. Underperforming sector by 5.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.31x) but short-term weakness (below SMA20). RSI neutral at 48. Volume at 41% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.48% (CS: 11) | Weak |
| RSI_14 | 48.1 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 0.964x | Below |
| vs SMA50 | 1.028x | Above |
| vs SMA200 | 1.309x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $42.49
- **Stop Loss:** $39.19 (7.8% risk)
- **Target:** $49.09 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 400
- **Position Value:** $16,996.00
- **Portfolio %:** 17.00%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*